This website provides information about the business field of CO.DON GmbH, which has taken over the business operations from CO.DON AG.
Information on CO.DON Aktiengesellschaft can be found at www.codon-aktiengesellschaft.de.
About CO.DON 
We specialise in the development and manufacture of cell therapies for the regenerative treatment of articular cartilage defects using only the patient’s own cartilage cells. Our cell therapies are a regenerative method that in many cases can make it possible to avert or postpone the need for joint replacement surgery. Our therapies are classified as prescription-only medicinal products and are increasingly used on a day-to-day basis in hospitals by orthopaedic and accident surgeons.
Our more than 100 employees come from many very different professional backgrounds - scientists, researchers, manufacturing and quality control specialists, engineers, experts for regulatory affairs, clinical trials, market access, communication and many other areas. Together they work every day to ensure that our company is a reliable partner for the physicians using our products in hospitals. Hand in hand, they guarantee the highest product quality for the benefit of patients and contract manufacturing customers.
As experts for human cells we want to provide a regenerative, personalised treatment for every patient using their own cells, which enables them to enjoy an active life. Our mission and vision statements express this: they sum up what we strive for and the commitments we make in our daily work. Our company values define the core elements of our corporate culture and thus what is important to us in our daily work as well as when cooperating with our colleagues and customers.
Established as a research-focused biotechnology company, we have since 2016 developed into a commercial biopharmaceutical, product-based company. In line with our mission and vision, we are currently working to make our cell therapies available not only to patients in Germany and the European Union, but also to other countries in Europe and beyond.
Establishment of co.don GmbH in Teltow (focus: contract research)
First company in Germany to receive manufacturing licence for autologous cell transplants under Section 13 German Pharmaceuticals Act (AMG)
First patient treated
Development of independent manufacturing technology – Integrated Isolator Technology (IIT) – and operational launch of proprietary cleanroom production plant
co.don GmbH becomes CO.DON AG
Initial public offering (IPO) on 14 February 2001
Start of clinical trials phase II and phase III
EU authorisation received and start of EU expansion
Construction start second production site at Leipzig
End of clinical trial phase II
End of clinical trial phase III
Start of routine production at the Leipzig site
Takeover of the operating business as CO.DON GmbH by ReLive Group
Consolidation of production sites
Our presence in Germany comprises the production and development site in Teltow. A further site is located in Leipzig. In addition, we have operations in the following European countries via subsidiaries or distribution partnerships: Switzerland (co.don schweiz gmbh), Netherlands (CO.DON NL Group B.V.), Austria and Great Britain.